US recommends ‘pause’ to Johnson & Johnson jab rollout over blood clot fears

The US Food and Drug Administration has recommended a “pause” to the rollout of the Johnson & Johnson COVID vaccine so it can investigate reports of blood clots.

Officials say they are looking into six reported cases “of a rare & severe type of blood clot in individuals after receiving the vaccine”.

“Right now, these adverse events appear to be extremely rare,” the FDA said in a statement on Twitter.

It said until the cases had been assessed for their potential significance, “we are recommending this pause”.

“This is important to ensure that the health care provider community is aware of the potential for these adverse events and can plan due to the unique treatment required with this type of blood clot,” it added.

Articles You May Like

California plans to send millions of ‘inflation relief’ payments of up to $1,050. Here’s what we know about whether other states will follow
Podcaster Dame Deborah James dies after battle with bowel cancer
Bitcoin just had its worst month on record
Aqua superPower turns on its first marine fast charger in US
‘Devastating’: Woodward calls Jan. 6 testimony Trump’s ‘political obituary’